Insulinorezistentnost' i povyshenie arterial'nogo davleniya - dve tseli antigipertenzivnoy terapii


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The review discusses the problem of pathogenetic relationship between insulin resistance (IR) and arterial hypertension (AH). Along with genetically determined IR, stress, overeating, obesity and hypodinamia are the leading factors for its development in 50 % of cases. The mechanism of tissue IR, the role of IR in the pathogenesis of AH, and requirements for antihypertensive therapy against the background of IR are presented. Comparative analysis of the major classes of antihypertensive drugs used for this purpose is demonstrated.

全文:

受限制的访问

作者简介

S. Nedogoda

参考

  1. Balkau B., Charles M.A. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet. Med 1999; 16:442-43.
  2. Barath A., Tun S., Nemeth I., et al. The profile of renal function over time in a cohort of pediatric heart transplant recipients. Pediatr. Nephrol 2006;10(21):1419-25.
  3. Baxter J.D., Young W.F., Webb P.L. Cardiovascular Endocrinology: Introduction. Endocrine Rev 2003;24(3):253-60.
  4. Bonin-Guillaume S., Herrmann F.R., Boillat D., et al. Insulinemia and leptinemia in geriatric patients: markers of the metabolic syndrome or of undernutrition? Arq Bras Endocrinol Metab 2006;2(50)304-12.
  5. Caballero A.E., Delgado A., Aguilar-Salinas C.A., et al. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: A placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 2004;89(8): 3943-48.
  6. Cesaretti M.L., Kohlmann O. Jr. Experimental models of insulin resistance and obesity: lessons learned. Arq Bras Endocrinol Metab 2006;2(50):190-97.
  7. Correia M.L., Rahmouni K. Role of leptin in the cardiovascular and endocrine complications of metabolic syndrome. Diabetes Obes Metab 2006;8(6):603-10.
  8. D'Orazio N. Obesity and immune function. Ann Ital Chir 2005;5(76):413-16.
  9. Dubinski A., Zdrojewicz Z. The role of leptin in the development of hypertension. Hig. Med Dosw 2006;60:447-52.
  10. Ernsberger P., Friedman J.E., Koletsky R.J. The 11-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease. J Hypertens 1997;15(l):S9-23.
  11. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Hi). JAMA 2001;285:2486-97.
  12. Fabian E., Varga A., Picano E., et al. Effect of simvastatin on endothelial function in cardiac syndrome X patients. Amer J Cardiol 2004; 94:652-55.
  13. Francischetti E.A., Genelhu V.A. Obesityhypertension: an ongoing pandemic. intern J Clin Pract 2007;2(6):269-80.
  14. Furnsinn C., Willson T.M., Brunmair B. Peroxisome proliferator-activated receptor-delta, a regulator of oxidative capacity, fuel switching and cholesterol transport. Diabetologia 2007;50(1):8-17.
  15. Garg A. Body fat distribution and metabolic derangements in patients with familial partial lipodystrophy associated with man-dibuloacral dysplasia. J Clin Endocrinol Metab 2004;89(9):4206-10.
  16. Grundy S.M., Brewer H.B. Yr., et al. National Heart, Lung, and Blood Institute, American College of Cardiology Foundation, American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;109:433-38.
  17. Guzder R.N., Gatling W., Mullee M.A., Burne C.D. Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes. Diabetologia 2006;49(11):49-55.
  18. Ihara S., Shimamoto K., Watanabe H., et al. An alpha1-receptor blocker reduces plasma leptin levels in hypertensive patients with obesity and hyperleptinemia. Hypertens Res 2006;10(29):805-11.
  19. International Diabetes Federation. http://www. idf.org/webdata/docs/IDF_Metasyndrome_ definition. - 2005.
  20. Knouff C., Auwerx J. Peroxisome proliferator-activated receptor-γ calls for activation in moderation: lessons from genetics and pharmacology. Endocrine Rev 2005;25(6):899-918.
  21. Koletsky R.J., Velliquette R.A., Ernsberger P. The role of I(1)-imidazoline receptors and of glucose and lipid metabolism in the SHROB model of metabolic syndrome X. Ann NY Acad Sci 2003;1009:251-61.
  22. Lara-Castro C., Garvey T. Diet, insulin resistance, and obesity: zoning in on data for Atkins dieters living in South Beach. J Clin Endocrinol Metab 2004;89(9):4197-205.
  23. Lavoie J.L., Sigmund C. Minireview: overview of the renin-angiotensin system - an endocrine and paracrine system. Endocrinology 2003;144(6):2179-83.
  24. Lawlor D.A., Davey Smith G., Ebrahim S. Statins for the primary prevention of cardiovascular disease. Diabetologia 2006;49(11):41-48.
  25. Lee C.-H., Olson P., Evans R.M. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003;144(6):2201-07.
  26. Liu Y.-M., Moldes M., Bastard J.-P, et al. Adiponutrin: a new gene regulated by energy balance in human adipose tissue. J Clin Endocrinol Metab 2004;89(6):2684-89.
  27. Mlinar B., Marc J., Janez A., Pfeifer M. Molecular mechanisms of insulin resistance and associated diseases. Clin Chim Acta 2007; 1-2(375):20-35.
  28. Muller M., den Tonkelaar I., Thijssen J. H.H, et al. Endogenous sex hormones in men aged 40-80 years. Eur J Endocrinology 2003;149:583-89.
  29. Neel J.V. Diabetes Mellitus: A Thrifty Genotype Rendered Detrimental by Progress? Am J Hum Genet 1962;14(4):353-62.
  30. Olivieri O., Ciacciarelli A., Signorelli D., et al. Aldosterone to Renin ratio in a primary care setting: the Bussolengo study. J Clin Endocrinol Metab 2004;89(9):4221-26.
  31. Poulsen P., Vaag A. Glucose and insulin metabolism in twins: influence of zygosity and birth weight. Twin Res 1999;319(7203):151-54.
  32. Rayner B. Advances in the treatment of diabetic renal disease: focus on losartan. Curr Med Res Opin 2004;3(20):359-67.
  33. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
  34. Reid J.L. Update on rilmenidine: clinical benefits. Amer J Hypertens 2000;3(6 Pt 2):106-07.
  35. Sanjuliani A.F., de Abreu V.G., Francischetti L.A. Selective imidazoline agonist moxonidine in obese hypertensive patients. Intern J Clin Pract 2006;60(5):621-29.
  36. Schmidt M.I., Duncan B.B., Vigo A., et al. Leptin and incident type 2 diabetes: risk or protection? Diabetologia 2006;9(49):2086-96.
  37. Shi Y., Taylor S., Tan S.-L., Sonenberg N. When translation meets metabolism: multiple links to diabetes. Endocrine Reviews 2003: 24(1):91-101.
  38. Spinar J., Vitovec J. Imidazole receptor agonists a new advance in the treatment of hypertension? Vnitr Lek 2000;2(46):122-25.
  39. Stein C.J., Colditz G.A. The epidemic of obesity. J Clin Endocrinol Metab 2004;89:2522-25.
  40. Stock S., Leichner P., Wong A.C. K. Ghrelin, peptide YY, glucose-dependent insulinotropic polypeptide, and hunger responses to a mixed meal in anorexic, obese, and control female adolescents. Clin Endocrinol 2002;56:203-06.
  41. Usui I., Fujisaka S., Yamazaki K., et al. Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients. Diabetes Res Clin Pract 2007;45(18):154-65.
  42. Velliquette R.A., Kossover R., Previs S.F., Ernsberger P. Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X. Naunyn Schmiedebergs Arch Pharmacol 2006;4(372):300-12.
  43. Vilarrasa N., Vendrell J., Maravall J., et al. IL-18: relationship with anthropometry, body composition parameters, leptin and arterial hypertension. Horm Metab Res 2006;8(38): 507-12.
  44. Wasim H., Al-Daahri N.M., Cherry R., et al. Relationship of serum adiponectin and resistin to glucose intolerance and fat topography in South-Asians. Cardiovasc Diabetol 2006;2:5-10.
  45. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications; Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: WHO Department of Noncommunicable Disease Surveillance, 1999.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##